Pathogen-reduced platelets for the prevention of bleeding
Editorial Group: Cochrane Haematological Malignancies Group
Published Online: 28 MAR 2013
Assessed as up-to-date: 25 FEB 2013
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, Stanworth S, Murphy MF. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009072. DOI: 10.1002/14651858.CD009072.pub2.
- Publication Status: New
- Published Online: 28 MAR 2013
|De Francisci 2004|
|van Rhenen 2003|
A: abstract only
Allo: treated with allogeneic stem cell transplantation
Auto: treated with autologous stem cell transplantation
BC: buffy coats
Ch: treated with chemotherapy, but without stem cell transplantation
C-O: cross-over trial
E: equivalence trial
F: full paper
NR: not reported
P2: parallel 2 arms
P3: parallel, 3 arms
SCT: treated with stem cell transplantation (undifferentiated)
*: Statistically significant lower mean platelet doses were issued for PCT versus standard platelet transfusions (P < 0.001 for Kerkhoffs 2010, McCullough 2004 and van Rhenen 2003). However, the doses in both arms were within the intermediate dose category of the PLADO study (Slichter 2010) in all of these studies. Although these differences were statistically significant overall there was less than a 10% difference in dose between the study arms in the three trials (range 8% (McCullough 2004) to 15% (Kerkhoffs 2010)).
#: Platelet dose has been categorised according to the low-dose, intermediate-dose and high-dose categories in the PLADO study (Slichter 2010). Low/intermediate means that the dose was between the low and intermediate categories of PLADO.
$: Cross-over design means adverse events (including mortality) were not assigned as specifically related to either PCT or standard transfusion.
£: Statistically significant difference between treatment arms for duration of platelet storage in McCullough 2004 (P = 0.03).
NA: not applicable
NR: not reported
P: prophylactic transfusion (threshold plt count x 10
PCT: photochemically treated
PP: pre-procedure transfusion (threshold plt count x 10
T: therapeutic transfusion
*: statistically significant difference in the number of platelet transfusions received per patient
#: on-protocol transfusions only
@: off-protocol transfusions only
(e) = scale expanded (defined WHO grades more specifically, including sites of bleeding)
L: long-term bleeding assessment (> 7 days) post-transfusion
(m) = scale modified(only 3 scores: none = 0, minor = 1 (equivalent to WHO grades 1 and 2), major = 2 (equivalent to WHO grades 3 and 4))
NA = not applicable
NR = not reported
S: short-term bleeding assessment (up to 48 hours) post-transfusion
* = on-protocol platelet transfusions only
1. WHO scale – WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation; 1979.
2. U.S. Dept of Health and Human Services (National Institutes of Health & National Cancer Institute). Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0, September 2006.